Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ocrelizumab No direct evidence (very low certainty).
1 finding from 1 review
RR 0.61 [0.41, 0.9]
Studies not reported
Very low
Intervention not reported
Glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower glatiramer acetate (Direct evidence; 2 RCTs; 1454 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).
1 finding from 1 review
RR 0.54 [0.38, 0.77]
Studies not reported
Very low
Intervention not reported
Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).
1 finding from 1 review
RR 1.19 [0.74, 1.91]
Studies not reported
Very low
Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
RR 0.63 [0.41, 0.96]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 1 RCT; 1088 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 1 RCT; 1088 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower alemtuzumab No direct evidence (moderate certainty).
1 finding from 1 review
OR 0.39 [0.19, 0.79]
Studies not reported
Moderate
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 54 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 54 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in cladribine (Direct evidence; 1 RCT; 1326 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab (Direct evidence; 1 RCT; 600 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher daclizumab (Direct evidence; 1 RCT; 600 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 91 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention probably leads to lower immunoglobulins (Direct evidence; 2 RCTs; 91 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher fingolimod (Direct evidence; 2 RCTs; 2355 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher glatiramer acetate (Direct evidence; 4 RCTs; 2419 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Immunoglobulins (Direct evidence; 3 RCTs; 243 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 3 RCTs; 243 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
OR 3.02 [0.27, 33.65]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) (moderate certainty).
1 finding from 1 review
OR 1.48 [0.99, 2.2]
1 study · 2 participants
Moderate